ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Currently, multiple clinical trials are evaluating the feasibility of combining asciminib with other TKIs used in CML treatment, as asciminib targets a different region on the BCR::ABL1 oncoprotein [160].